title: Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice.
abstract: Incorporation of the alpha5 nicotinic acetylcholine receptor (nAChR) subunit can greatly influence nAChR function without altering receptor number. Although few animal studies have assessed the role of the alpha5 nAChR in nicotine-mediated behaviors, recent evidence suggests an association between polymorphisms in the alpha5 nAChR gene and nicotine dependence phenotypes in humans. Thus, additional studies are imperative to elucidate the role and function of the alpha5 nAChR subunit in nicotine dependence. Using alpha5(-/-) mice, the current study aimed to examine the role of alpha5 nAChRs in the initial pharmacological effects of nicotine, nicotine reward using the conditioned place preference model, and the discriminative effects of nicotine using a two-lever drug discrimination model. (86)Rb(+) efflux and (125)I-epibatidine binding assays were conducted to examine the effect of alpha5 nAChR subunit deletion on expression and activity of functional nAChRs. Results show that alpha5(-/-) mice are less sensitive to the initial effects of nicotine in antinociception, locomotor activity, and hypothermia measures and that the alpha5 nAChR is involved in nicotine reward. Alternatively, alpha5(-/-) mice did not differ from wild-type littermates in sensitivity to the discriminative stimulus effects of nicotine. Furthermore, deletion of the alpha5 nAChR subunit resulted in a statistically significant decrease in function in the thalamus and hindbrain, but the decreases noted in spinal cord were not statistically significant. Receptor number was unaltered in all areas tested. Taken together, results of the study suggest that alpha5 nAChRs are involved in nicotine-mediated behaviors relevant to development of nicotine dependence.
authors.affiliation: Department of Psychiatry, Pharmacology/Toxicology, Virginia Commonwealth University, Richmond, VA 23298-0613, USA. jacksonkj@vcu.edu
authors.forename: K J
authors.initials: KJ
authors.lastname: Jackson
authors.forename: M J
authors.initials: MJ
authors.lastname: Marks
authors.forename: R E
authors.initials: RE
authors.lastname: Vann
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: T F
authors.initials: TF
authors.lastname: Gamage
authors.forename: J A
authors.initials: JA
authors.lastname: Warner
authors.forename: M I
authors.initials: MI
authors.lastname: Damaj
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001831:Body Temperature; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007035:Hypothermia / Q000139:chemically induced / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009020:Morphine / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology; D010146:Pain / Q000378:metabolism; D017288:Pain Threshold / Q000187:drug effects; D011485:Protein Binding; D011978:Receptors, Nicotinic / Q000235:genetics / Q000502:physiology*; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
chemical_list: D000701:Analgesics, Opioid; D009020:Morphine; D009538:Nicotine; D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; C523972:CHRNA5 protein, mouse
references.citation: J Neurosci. 1999 Nov 1;19(21):9298-305
references.pmid: 10531434
references.citation: J Neurochem. 2008 Jan;104(2):446-56
references.pmid: 17961152
references.citation: J Pharmacol Exp Ther. 1998 Jul;286(1):311-20
references.pmid: 9655874
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):331-6
references.pmid: 12769607
references.citation: J Neurosci. 2002 Oct 15;22(20):8785-9
references.pmid: 12388584
references.citation: J Neurosci. 2000 Sep 1;20(17):6431-41
references.pmid: 10964949
references.citation: J Neurochem. 2000 Jul;75(1):18-27
references.pmid: 10854242
references.citation: Nature. 1998 Jan 8;391(6663):173-7
references.pmid: 9428762
references.citation: Physiol Genomics. 2004 Apr 13;17(2):221-9
references.pmid: 14996991
references.citation: J Pharmacol Exp Ther. 1999 Oct;291(1):390-8
references.pmid: 10490929
references.citation: J Biol Chem. 1996 Jul 26;271(30):17656-65
references.pmid: 8663494
references.citation: J Pharmacol Exp Ther. 2007 Jul;322(1):399-407
references.pmid: 17446302
references.citation: J Pharmacol Exp Ther. 1998 Apr;285(1):377-86
references.pmid: 9536034
references.citation: J Mol Neurosci. 2010 Jan;40(1-2):91-5
references.pmid: 19693710
references.citation: Mol Pharmacol. 2004 Jun;65(6):1526-35
references.pmid: 15155845
references.citation: J Neurochem. 2007 Oct;103(1):204-15
references.pmid: 17573823
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):1161-9
references.pmid: 17371806
references.citation: J Pharmacol Exp Ther. 2008 Apr;325(1):302-12
references.pmid: 18184829
references.citation: J Pharmacol Exp Ther. 1999 May;289(2):1090-103
references.pmid: 10215692
references.citation: Mol Psychiatry. 2008 Apr;13(4):368-73
references.pmid: 18227835
references.citation: PLoS Genet. 2008 Jul 11;4(7):e1000125
references.pmid: 18618000
references.citation: Nature. 1996 Mar 28;380(6572):347-51
references.pmid: 8598930
references.citation: Brain Res. 1990 Aug 27;526(1):45-53
references.pmid: 2078817
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1102-11
references.pmid: 17597586
references.citation: J Neurosci. 2009 Mar 11;29(10):3014-8
references.pmid: 19279237
references.citation: Hum Mol Genet. 2007 Jan 1;16(1):36-49
references.pmid: 17135278
references.citation: Nature. 1999 Apr 29;398(6730):805-10
references.pmid: 10235262
references.citation: Science. 2004 Nov 5;306(5698):1029-32
references.pmid: 15528443
references.citation: Psychopharmacology (Berl). 2006 Mar;184(3-4):339-44
references.pmid: 16416156
references.citation: Neuropharmacology. 2002 Mar;42(4):530-9
references.pmid: 11955523
references.citation: Mol Pharmacol. 2002 Mar;61(3):695-705
references.pmid: 11854451
references.citation: Psychopharmacology (Berl). 2007 Feb;190(2):157-70
references.pmid: 17115136
references.citation: J Pharmacol Exp Ther. 1998 Mar;284(3):1058-65
references.pmid: 9495867
references.citation: Neuropharmacology. 2007 Sep;53(3):390-405
references.pmid: 17631923
references.citation: J Neurosci. 1992 Jul;12(7):2765-84
references.pmid: 1613557
references.citation: Mol Pharmacol. 2007 Mar;71(3):769-76
references.pmid: 17132685
references.citation: Nature. 2008 Apr 3;452(7187):638-642
references.pmid: 18385739
references.citation: Am J Psychiatry. 2008 Sep;165(9):1163-71
references.pmid: 18519524
references.citation: Mol Pharmacol. 2003 May;63(5):1059-66
references.pmid: 12695534